Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

450
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
450
Angina IV: Management01:26

Angina IV: Management

495
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
495
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

747
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
747
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

659
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
659

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Pilot feasibility study of intraprocedural transcranial Doppler monitoring to assess Heal coating thrombogenicity in flow diversion.

Frontiers in neurology·2026
Same author

MAD-MT Score: A Tool to Optimize Patient Selection for Mechanical Thrombectomy in Distal Vessel Occlusions.

Stroke·2026
Same author

Clopidogrel versus ticagrelor in dual antiplatelet therapy for flow diversion of unruptured intracranial aneurysms: analysis of the Neurovascular Quality Initiative-Quality Outcomes Database (NVQI-QOD) Cerebral Aneurysm Registry.

Journal of neurointerventional surgery·2026
Same author

Distinct Clinical Phenotypes in Moyamoya Disease: A Multicenter Comparison of Ischemic and Hemorrhagic Presentations.

Neurosurgery·2026
Same author

International multi-center study to quantify the effect of deep venous drainage after surgical resection of Spetzler-Martin Grade II-III brain arteriovenous malformations.

Neurosurgical review·2026
Same author

Woven Endobridge device for ruptured vs. unruptured aneurysms: insights from the WorldWideWEB study.

Neuroradiology·2026

相关实验视频

Updated: May 6, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

25.7K

现代 Carotid Revascularization:对 Carotid Endarterectomy,Carotid Angioplasty 和 Stenting 的比较审查,以及 Transcarotid 动脉的再血管化

Abdelaziz Amllay1, Andrew B Koo1, Daniela Renedo1

  • 1Department of Neurosurgery, Yale University, Yale-New Haven Hospital, New Haven, Connecticut, United States.

Seminars in neurology
|September 1, 2025
PubMed
概括

动脉狭窄增加了中风的风险. 冠状动脉内切除术 (CEA),冠状动脉移植术 (TF-CAS) 和跨冠状动脉再血管化 (TCAR) 是可能的选择,其中TCAR显示出有前途.

更多相关视频

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.1K
A Magnetic Resonance Imaging-based Computational Protocol for Analysis of Plaque Morphology and Hemodynamics in Patients with Carotid Artery Stenosis
09:36

A Magnetic Resonance Imaging-based Computational Protocol for Analysis of Plaque Morphology and Hemodynamics in Patients with Carotid Artery Stenosis

Published on: August 12, 2025

67

相关实验视频

Last Updated: May 6, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

25.7K
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.1K
A Magnetic Resonance Imaging-based Computational Protocol for Analysis of Plaque Morphology and Hemodynamics in Patients with Carotid Artery Stenosis
09:36

A Magnetic Resonance Imaging-based Computational Protocol for Analysis of Plaque Morphology and Hemodynamics in Patients with Carotid Artery Stenosis

Published on: August 12, 2025

67

科学领域:

  • 血管外科
  • 神经学
  • 干预心脏病学

背景情况:

  • 动脉狭窄是导致缺血性中风的主要原因.
  • 指导方针建议对≥50%的症状狭窄和≥70%的无症状狭窄进行干预.
  • 最佳的医疗疗法至关重要,

研究的目的:

  • 提供当前动脉复血管化策略的比较审查.
  • 分析临床指示,手术技术和结果.
  • 为选择治疗提供个性化的风险/益处评估.

主要方法:

  • 对现有证据进行比较审查.
  • 对动脉内关节切除术 (CEA),动脉输血整形术和支架 (TF-CAS) 以及动脉再血管化 (TCAR) 的数据进行分析.
  • 对安全性和疗效的评估.

主要成果:

  • 对于动脉复血管化来说,
  • 对于高危患者来说,TF-CAS和TCAR是安全的替代品.
  • 在某些患者中,TCAR的安全性和疗效与CEA相美,可能优于TF- CAS.

结论:

  • 选择治疗需要进行多学科,个性化的风险/益处评估.
  • 这是一个新兴的,有效的选择,
  • 证据支持TCAR作为CEA的可行替代品,并可能优于TF-CAS.